Mizuho Upgrades Cepheid to Buy | GenomeWeb

NEW YORK (GenomeWeb News) – Investment firm Mizuho late on Thursday upgraded Cepheid to a Buy rating, calling the Sunnyvale, Calif.-based molecular diagnostics firm "a best-in-class diagnostics company."

Analyst Peter Lawson upgraded Cepheid from a Neutral rating, although he lowered estimates to take into account potential lingering issues with the company's manufacturing capabilities, as well as a slower than expected uptake of new products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.